After hours

Halozyme Therapeutics, Inc.

HALO · Nasdaq

Analyst Consensus

Buy

13 analysts

$129

Current

—

Low

$100

Average

—

High

Average target implies -22.22% versus the current price.

Analyst Ratings Synthesis

The supplied evidence does not establish one reliable consensus dataset. Public.com reports a Buy consensus from nine analysts as of September 4, 2026, while other aggregators show materially different figures: Fintel cites an average target of $86.19 with a $56.56-$100.80 range, and TickerGate reports 27 analysts averaging $76.14 with a $56-$94 range. Simply Wall St. says its target was reduced to $83.90 from $85.78 after mixed revisions. The evidence does not name the most or least bullish individual analyst, nor does it provide a complete rating count. The substantive disagreement is whether strong revenue and royalty growth justify the valuation and targets.

Rating Actions

No individual rating actions have been captured for HALO yet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

BERENBERG BANK

CITIZENS JMP

CO FORECST

GOLDMAN SACHS

H C WAINWRIGHT

JEFFERIES & CO.

JP MORGAN SECUR

LEERINK PARTNRS

MORGAN STANLEY

PIPER SANDLER

STONEX FINANCIA

WELLS FARGO SEC

ZACKS RESEARCH

Symbol: HALO
Type: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
Country: North America
Exchange: Nasdaq

Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution facilitates the subcutaneous delivery of injected drugs and fluids, reducing treatment burden and improving convenience. ENHANZE has touched more than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, Merus N.V., GSK, and Incyte. Halozyme expanded its drug delivery technology portfolio to develop partner products using Hypercon and Surf Bio's hyperconcentration technology, recently renamed as Aerocon.

Key Issues

Bullish view

Strong royalty growth and record revenue growth support the view that Halozyme’s asset-light model can continue expanding earnings and cash generation.

Bearish view

Simply Wall St. argues that the stock could be overvalued despite strong royalty growth, implying that expectations and valuation may already discount substantial future expansion.

Analyst Consensus

See all

Buy

13 analysts

$129

Current

—

Low

$100

Average

—

High

Average target implies -22.22% versus the current price.

Earnings History

BeatMissNo estimate

Halozyme Therapeutics, Inc.

Analyst Consensus

Analyst Ratings Synthesis

Rating Actions

Research Reports

Covering Firms

Peers